Dutasteride for the treatment of benign prostatic hyperplasia

@article{Wu2013DutasterideFT,
  title={Dutasteride for the treatment of benign prostatic hyperplasia},
  author={C. Wu and A. Kapoor},
  journal={Expert Opinion on Pharmacotherapy},
  year={2013},
  volume={14},
  pages={1399 - 1408}
}
  • C. Wu, A. Kapoor
  • Published 2013
  • Medicine
  • Expert Opinion on Pharmacotherapy
    • Introduction: Benign prostatic hyperplasia (BPH) is an age-related phenomenon associated with prostatic enlargement and bladder outlet obstruction that can cause significant lower urinary tract symptoms that greatly affect quality of life. Dutasteride is a selective inhibitor of type 1 and type 2 isoforms of 5-α-reductase, an enzyme responsible for the conversion of testosterone to 5-α-dihydrotestosterone, approved as a treatment for symptomatic BPH. Areas covered: This article will cover the… CONTINUE READING
    View on Taylor & Francis
    ncbi.nlm.nih.gov
    15 Citations
    Highly Influential Citations
    1
    Background Citations
    6
    Results Citations
    1
    15 Citations
    Citation Type

    Citation Type

    Benign Prostatic Hyperplasia : Review and Update on Etiopathogenesis and Treatment Modalities
    • 2
    • PDF
    Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia
    • 9
    • PDF
    Effects of dutasteride on serum free‐testosterone and clinical significance of testosterone changes
    • 3
    • Highly Influenced
    Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes.
    • 13
    • PDF
    Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know?
    • 58
    Dutasteride‐mediated morphological changes in the genitourinary tract associated with altered expression patterns of the androgen and estrogen receptors in male rats
    • 4
    A phytosterol-enriched saw palmetto supercritical CO2 extract ameliorates testosterone-induced benign prostatic hyperplasia by regulating the inflammatory and apoptotic proteins in a rat model
    • 4
    Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement
    • T. Maeda, E. Kikuchi, +7 authors M. Oya
    • Medicine
    • International journal of urology : official journal of the Japanese Urological Association
    • 2018
    • 4
    Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data
    • Jamal Shamsara
    • Computer Science, Medicine
    • Interdisciplinary Sciences: Computational Life Sciences
    • 2018
    • 1
    Relative Bioavailability of Fixed‐Dose Combinations of Tamsulosin and Dutasteride: Results From 2 Randomized Trials in Healthy Male Volunteers
    • 1

    References

    SHOWING 1-10 OF 42 REFERENCES
    The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    • 546
    • Highly Influential
    The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    • 1,610
    • PDF
    Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    • 223
    The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
    • 881
    The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia
    • 51
    • PDF
    5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    • R. Rittmaster
    • Medicine
    • Best practice & research. Clinical endocrinology & metabolism
    • 2008
    • 54
    The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    • 319
    [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    • 51
    Benign prostatic hyperplasia: an overview.
    • 224
    • Highly Influential
    Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
    • 635
    • Highly Influential